Skip to main content
. Author manuscript; available in PMC: 2015 Aug 1.
Published in final edited form as: Schizophr Res. 2014 May 28;157(0):84–89. doi: 10.1016/j.schres.2014.04.037

Figure 2.

Figure 2

Excess Kynurenic acid (KYNA) is associated with cognitive impairments in schizophrenia. Galantamine and Memantine combination may target α7nACh-R and NMDA-R respectively to decrease KYNA thereby improving cognitive impairments.